Background It has been suggested that, when a patient has giant cell tumor of bone (GCTB), subchondral bone involvement close to articular cartilage and a hyperthermic reaction from polymethylmethacrylate (PMMA) are risk factors for the development of osteoarthritis. We determined the prevalence, risk factors, and clinical relevance of osteoarthritis on radiographs after curettage and application of PMMA for the treatment of GCTB around the knee. Methods This retrospective single-center study included 53 patients with GCTB around the knee treated with curettage and PMMA between 1987 and 2007. The median age at the time of follow-up was 42 years (range 23-70 years). There were 29 women. Radiographic evidence of osteoarthritis was defined, preoperatively and postoperatively, as Kellgren and Lawrence grade 3 or 4 (KL3-4). We studied the influence of age, sex, tumor-cartilage distance, subchondral bone involvement (≤3 mm of residual subchondral bone), subchondral bone grafting, intra-articular fracture, multiple curettage procedures, and complications on progression to KL3-4. Functional outcomes and quality of life were assessed with the Short Form-36 (SF-36), Musculoskeletal Tumor Society (MSTS) score, and Knee injury and Osteoarthritis Outcome Score (KOOS). Results After a median duration of follow-up of 68 months (range 60-285 months), six patients (11%) had progression to KL3, two (4%) had progression to KL4, and one had preexistent KL4. No patient underwent total knee replacement. The hazard ratio for KL3-4 was 9.0 (95% confidence interval [CI]=2.0-41; p=0.004) when >70% of the subchondral bone was affected and 4.2 (95%CI=0.84-21; p=0.081) when the tumorcartilage distance was ≤3 mm. Age, sex, subchondral bone-grafting, intra-articular fracture, multiple curettage procedures, and complications did not affect progression to KL3-4. Patients with KL3-4 reported lower scores on the KOOS symptom subscale (58 versus 82; p=0.01), but their scores on the other KOOS subscales, the MSTS score (21 versus 24), and the SF-36 (76 versus 81) were similar to those for the patients with KL0, 1, or 2 (KL0-2). Conclusion Seventeen percent of patients with GCTB around the knee had radiographic findings of osteoarthritis after treatment with curettage and PMMA. A large amount of subchondral bone involvement close to articular cartilage increased the risk for osteoarthritis. The function and quality of life
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Introduction
Giant cell tumor of bone (GCTB) is a benign primary bone tumor with a locally aggressive character. Usually, giant cell tumor occurs between thirty and fifty years of age [1] [2] [3] . GCTB is usually localized to the meta-epiphyseal area of long bones; 50% are located around the knee [1] . Approximately 1% to 4% of patients develop benign pulmonary metastases [1, [4] [5] [6] [7] [8] .
Standard treatment for GCTB consists of extended curettage and chemical adjuvants such as phenol, alcohol, hydrogen peroxide, argon laser, or liquid nitrogen [3, [9] [10] [11] [12] [13] [14] [15] . The remaining cavity can be left empty awaiting new bone formation during partial immobilization [16] [17] [18] , or it may be filled with cancellous bone graft [2, 19, 20] . However, reported recurrence rates following both options are high (27% to 65%) [1, 10] . At present, the most commonly used filling material is polymethylmethacrylate (PMMA), which is associated with a lower recurrence risk (12% to 34%), provides immediate mechanical support, and facilitates easy and early detection of local recurrences [9, 10, 21] . PMMA is therefore widely recommended to fill the cavity left after curettage [3, [9] [10] [11] [12] [13] 21] . However, it has been suggested that curettage and PMMA may result in secondary osteoarthritis, although risk factors for this development remain unclear ( Figure 1 ) [2, 13, 17, [22] [23] [24] [25] [26] [27] [28] [29] . PMMA is a thermal adjuvant increasing surgical margins up to 1.5 to 2 mm in cancellous bone and 0.5 mm in cortical bone [23] [24] [25] . Degenerative changes may be caused by this hyperthermic polymerization of PMMA [13, 17, 23, 24] , but a close relation of the tumor with articular cartilage and extensive subchondral bone involvement may be more important risk factors [22, [25] [26] [27] . In addition, often large volumes of PMMA are used after curettage for GCTB, with possible increased thermal damage [24] . Finally, intra-articular pathologic fracture [28, 29] and repeated curettage with application of PMMA for recurrences are also believed to increase the risk for degenerative changes [2, 28] . Follow-up radiographs demonstrate KL1-2 after fifty-five months, (C) KL3 after sixty-seven months and (D) KL4 after ten years. This patient underwent repeated curettage and application of PMMA for three recurrences. There was no evidence of GCTB at the time of final follow-up.
Therefore, we evaluated (1) the prevalence of radiographic findings of osteoarthritis after treatment for GCTB around the knee with curettage and PMMA; (2) which patient, treatment, and tumor characteristics are associated with the risk of progression to osteoarthritis; and (3) the clinical relevance, as determined with functional outcome and quality-of-life scores, of radiographic findings of osteoarthritis.
Materials and methods
We retrospectively evaluated 68 patients treated with curettage and PMMA for GCTB in the distal part of the femur or the proximal part of the tibia from 1987 to 2007. These patients were identified from the total group of 189 consecutive patients who had been treated for GCTB at our tertiary referral center during that period. The minimum duration of follow-up was five years. Fifteen patients were excluded: nine patients had missing preoperative radiographs, four patients had been treated with resection and endoprosthetic reconstruction for recurrence, and two patients had died of causes unrelated to the GCTB, all within five years after index surgery. We included 53 patients (29 of whom were female) with GCTB around the knee, with a median duration of follow-up of 86 months (range 60-285 months). The median age at the index surgery was 32 years (range 16-62 years). Two patients had multicentric GCTB. None of the included patients developed pulmonary metastases. No patient was recalled specifically for this study. This study was approved by the institutional medical ethics committee. The initial surgery was performed by fellowship-trained oncological orthopaedic surgeons. At our center, intralesional treatment was preferred for GCTB even in the presence of soft-tissue extension and intra-articular pathologic fracture [30, 31] . En bloc resection was almost never performed as primary treatment for GCTB. Standard treatment consisted of curettage, local application of phenol and ethanol, and rinsing the cavity with high-speed pulse lavage with saline solution. During the evaluated time frame, high-speed burring was not standard at our center. In eight patients, no phenol was applied as adequate protection of surrounding tissues was impossible due to cortical defects. Subchondral cancellous bone grafting was considered after curettage when <10 mm of subchondral bone remained, and was performed in 25 patients. The cavity was filled with PMMA in all patients. Cementation was performed under tourniquet control. The cement volume depended on the size of the GCTB and averaged 30 to 60 mL. Postoperative treatment consisted of functional mobilization and immediate weight-bearing for most patients. Those with a pathologic fracture were permitted only partial weight-bearing for 6 to 12 weeks. There were no restrictions on sports or activities six months postoperatively. The follow-up protocol consisted of conventional radiographs after 1.5, 3, 6, 12, 18 and 24 months and yearly up to ten years to detect recurrences and complications. Chest radiography to detect pulmonary metastases and magnetic resonance imaging (MRI) were performed after one, two, five, and ten years. Medical records and radiographs were reviewed to determine age, sex, localization, tumor-cartilage distance, subchondral bone involvement, intraarticular pathologic fractures, subchondral bone grafting, multiple curettage and PMMA procedures for recurrence, complications, preoperative and postoperative Kellgren and Lawrence (KL) grades, and duration of follow-up (Table 1 ). All data were complete. KL grading was used to assess osteoarthritis on preoperative and postoperative anteroposterior non-weight-bearing radiographs [32] . Two observers each performed the grading twice. When three of four KL grades corresponded, that grade was assigned. When the two observers assigned different KL grades, consensus was reached. We defined KL grade-3 or 4 (KL3-4) osteoarthritis [32] [33] [34] as moderate to pronounced osteophyte formation, definite joint space narrowing, and subchondral sclerosis ( Table 2 ; Figure 1 ). The time until signs of osteoarthritis appeared was determined on follow-up radiographs. We assessed the influence of age, sex, follow-up duration, tumor-cartilage distance, subchondral bone involvement, subchondral bone grafting, intraarticular pathologic fractures, number of curettage and PMMA procedures, and complications on osteoarthritis development. The amount of subchondral bone involvement was defined as the area of the involved knee compartment in which ≤3 mm of subchondral bone thickness remained ( Figure 2 ); this was calculated as a percentage with a method similar to that described by Chen et al. [26] . Measurements were performed once by each of two observers.
Figure 2
The amount of subchondral bone involvement by the GCTB was defined as the area of the femoral or tibial condyle in which there was ≤3 mm of subchondral bone thickness remaining. This was calculated, with a method similar to that described by Chen et al. as a percentage: (a/A) x 100% or (b/B) x 100% [26] .
Functional outcomes and quality of life were evaluated with the Musculoskeletal Tumor Society (MSTS) score, Knee injury Osteoarthritis Outcome Score (KOOS), and Short Form-36 (SF-36) [35] [36] [37] . Questionnaires were obtained by mail at a mean of 11 years (range 5-25 years) after the initial surgery. Nine patients did not return questionnaires, so patient-reported outcome measures were available for 44 patients (83%).
Statistical analysis
Kaplan-Meier methodology was applied to assess the probability of progression to KL3-4. As no patient died, this probability can be estimated as one minus survival function. Univariate and multivariate (for relevant variables) Cox regression was performed to determine risk factors for radiographic osteoarthritis. Chi-square and Fisher exact tests were employed for dichotomous variables whereas nonparametric Mann-Whitney U tests were used for numerical data. Cohen's kappa statistic was used to determine interobserver and intraobserver agreement for KL3-4 and interobserver agreement for subchondral bone involvement. Outstanding agreement was defined as κ>0.80; substantial agreement as κ=0.60-0.79; moderate agreement as κ=0.40-0.59; and poor agreement as κ<0.40 [38, 39] .
Results
Six patients (11%) had progression from KL0-1 to KL3 and two (4%) from KL0-1 to KL4, the signs of which appeared on postoperative radiographs after a median of 57 months (mean 98 months; range 33-285 months); one patient had preexistent KL4. At the time of writing, none of these patients had required total knee arthroplasty. Figure 3 shows that the probability of progression to KL3-4 has not reached a plateau phase by the time of this study, indicating that the prevalence of KL3-4 grades may increase with time. In all patients, degenerative changes were localized to the involved knee compartment. Eighty-three percent of the patients did not develop radiographic findings of osteoarthritis: for 20 patients (38%), the grade remained stable at KL0-2; 14 patients (26%) had progression from KL0 to KL1; five (9%) had progression from KL0 to KL2; and five (9%) had progression from KL1 to KL2. [38, 39] .
Figure 3
Kaplan Meier one minus survival curve of the probability of progression to KL3-4, which was 8% at five years and 18% at ten years after curettage and application of PMMA for GCTB around the knee joint.
In 26 patients, ≤3 mm of subchondral bone remained after curettage; their mean subchondral bone involvement was 49% (range 7%-100%). Sixteen of these patients were treated with subchondral bone graft. The mean subchondral bone involvement was 56% (range 10%-100%) in patients treated with subchondral bone graft and 38% (range 7%-85%) in patients not treated with subchondral bone graft (p=0.007). Six of the 16 patients who received bone graft and one of the ten patients who did not receive bone grafts developed radiographic evidence of osteoarthritis (KL3-4). When more subchondral bone was affected, the risk of development of KL3-4 increased, with a hazard ratio (HR) of 18 (95%CI=2.4-140; p=0.005) ( Table 3 ). This risk was most apparent when >70% of the subchondral bone was involved by giant cell tumor, with an HR of 9.0 (95%CI=2.0-41, p=0.004). The HR for a tumor-cartilage distance of ≤3 mm was 4.2 (95%CI=0.84-21; p=0.081). Fifteen patients (28%) underwent repeat curettage and application of PMMA because of recurrences (nine had two repeat curettage procedures, four had three, and two had four). Three of the 15 patients with repeat curettage had KL3-4 at the time of follow-up. The prevalence of KL3-4 in patients with repeat curettage was not higher than that in the patients with a single surgical intervention (six of 38; p=0.63). The recurrence rate was comparable between the patients treated with subchondral bone graft and PMMA (nine of 25) and those treated with PMMA alone (six of 28) (p=0.36). Of the nine patients with recurrence after subchondral bone grafting, only two had the recurrence in the subchondral area; the other recurrences were at the PMMA-bone junction.
There were seven complications: three patients had pain, two had postoperative fracture, one had pseudoarthrosis, and one had infection. In all cases, the PMMA was replaced with bone graft. Two of these patients had KL3-4 at the time of follow-up; one underwent high tibial osteotomy to correct varus deformity after fracture. An age at the time of final follow-up of more than 60 years, a follow-up duration of more than ten years, female sex, and intra-articular fracture did not significantly influence the development of KL3-4 at the time of follow-up (Table  3 ). Cohen's kappa statistic for interobserver agreement on subchondral bone involvement was substantial with κ=0.76 (95%CI=0.58-0.94; p<0.001) [38, 39] . The functional outcome and quality of life were compared between different KL grades. There were no data from the one patient with preexistent KL4. Patients with KL3-4 reported lower scores only on the KOOS symptom subscale compared with patients with KL0-2 (p=0.01). The scores on the other KOOS subscales, MSTS, and all SF-36 subscales were similar between groups (Table  4) . Patients with KL4 reported lower scores only on the KOOS sports/recreation subscale when compared with patients with KL0-3 (p=0.044).
Discussion
The intralesional treatment of GCTB with curettage, local adjuvants, and PMMA was hypothesized to increase the risk for degenerative changes [13, 17, 23, 24] . A close relation with the articular cartilage, extensive subchondral bone defects, and larger tumor size, all characteristic of GCTB, are the most important factors for the development of osteoarthritis [22, [24] [25] [26] [27] . Additionally, intra-articular pathologic fractures [28, 29] and multiple curettage and PMMA procedures have also been mentioned as possible risk factors [2, 28] . In summary, risk factors for knee osteoarthritis after this surgical procedure remain unclear. Furthermore, quantification of degenerative changes after treatment for GCTB around the knee was presented in only two prior studies [28, 40] . Therefore, we determined the prevalence of radiographic findings of osteoarthritis after curettage and application of PMMA for giant cell tumor around the knee, risk factors for progression to KL3-4 after this surgical procedure, and the functional outcomes and quality of life following the procedure. Seventeen percent of patients had KL3-4 after curettage and application of PMMA for GCTB around the knee, a ten-fold increase compared with age-matched cohorts (0.3% to 1.8%) of the general population [34] . In the literature, the prevalence of osteoarthritis after curettage and application of PMMA has ranged from 4% to 25% in the upper and lower extremities [2, 3, 13, 17, 18, 22, 28, 41, 42] (Table 5) . At the time of writing, none of our patients had required total knee replacement. *Only patients with GCT around the knee are listed in this table **Number given for total group and not specified for GCT around the knee ***Not definition of good and excellent †This patient presented had intra-articular pathologic fracture † †One patient underwent total knee replacement † † †This study compared degenerative changes after curettage with either bone grafts or PMMA. The authors controlled for confounding by excluding GCT with potential risk factors for secondary osteoarthritis (e.g. pathologic fractures, complications and recurrences). §Eight patients underwent endoprosthetic replacement and three patients total knee replacement § §Three patients underwent total knee replacement PMMA -polymethylmethacrylate, BG -bone grafts, LKS -Lysholm Knee Score, MSTS -Musculoskeletal Tumor Society score, SF-36 -Short-Form Health Survey 36, OA -osteoarthritis
In our study of GCTB treated with curettage and PMMA, tumor size and proximity to joint surface were strongly associated with radiographic findings of osteoarthritis, confirming earlier results [24] [25] [26] [27] . The risk of arthritis was increased nine-fold when >70% of the subchondral bone within 3 mm of articular cartilage was affected. If ≤3 mm of cancellous bone is spared by tumor, both the subchondral bone layer and articular cartilage can be exposed to necrotic effects of curettage, phenol application, and PMMA polymerization [25] . Along with others, we could not confirm whether the risk of osteoarthritis could be attributed to the use of PMMA, intralesional treatment, or characteristics of the GCTB, as there was no control group in this study [3] . Szalay et al. compared degenerative changes in two groups, treated with cement or bone graft, and found that the risk of osteoarthritis was increased for the bone graft group in the first two postoperative years, until full incorporation of the bone graft, and was increased in the PMMA group thereafter [22] . Placing subchondral bone graft in large subchondral bone defects may protect cartilage from degenerative changes by increasing the distance between the articular cartilage and the bone cement, thus creating a buffer against the thermal effects of PMMA on the joint cartilage [2, 17, 22] . In the present study, subchondral bone graft was used in patients with subchondral bone defects close to the joint, but we found no decrease in the prevalence of osteoarthritis, probably because the subchondral defects were larger in the patients treated with bone graft. These patients had a higher a priori risk for developing KL3-4 osteoarthritis compared with patients with less tumor involvement of subchondral bone. This suggests that articular damage may be caused by the curettage itself or by tumor characteristics rather than by thermal damage from PMMA; however, without a control group, this remains uncertain. Furthermore, it was hypothesized that recurrences would be more likely to appear at the site of bone grafting because of absent thermal effects of PMMA, but we could not confirm this finding. Repeat curettage and PMMA procedures for recurrences have been suggested to increase the risk of osteoarthritis [2, 28] , but that was not found in our series. The relatively high recurrence rate in our study may partly be explained by the fact that we did not perform extended curettage including high-speed burring during the evaluated time frame. Now, high-speed burring is performed whenever it is technically possible. However, the largest confounder of the high recurrence rate is our wide indication for curettage, including the majority of patients with soft-tissue extension and pathologic fracture. En bloc resection is rarely the primary treatment for GCTB at our center [30, 31] . Intra-articular pathologic fractures have also been suggested to increase the risk for osteoarthritis, but we could not confirm that finding [28, 29] . Finally, we found no association between osteoarthritis and sex, age over sixty years, follow-up longer than ten years, or complications, but most patients were relatively young and osteoarthritis may appear with longer follow-up [34] . The functional outcome and quality-of-life scores were comparable between the patients with KL3-4 and those with KL0-2, and quality of life was comparable with that of age-matched cohorts of the general population [37] . Despite radiographic evidence of osteoarthritis in a small group of our patients, it is likely not a clinical concern at the time of mid-term follow-up. Yet this clinical relevance may increase with time, and longer follow-up is required.
The discrepancy between the degree of osteoarthritis and clinical symptoms was found in 33% of patients with osteoarthritis in a previous study [34] . Other investigators have reported similar functional results and quality of life after curettage with and without PMMA [3, 12, 13, 22, 26] , but no previous study to our knowledge compared functional results and quality of life between patients with and those without osteoarthritis after curettage and PMMA. Only Chen et al. demonstrated a decrease of 3% in the MSTS score for every 10% increase in subchondral bone involvement [26] . Since the risk of osteoarthritis was not increased after repeat curettage and application of PMMA, we concluded that PMMA is a safe material and that curettage is a good treatment option for primary and recurrent GCTB. When progression to KL3-4 is noted and patients have severe physical symptoms, PMMA may be removed and replaced with cancellous bone graft, potentially facilitating total knee replacement in the future. In future, PMMA substitutes with similar hyperthermic effects, better osteoconductive and osteoinductive properties, and more favorable elasticity may be used [43] [44] [45] . Resection and endoprosthetic replacement as primary treatment for GCTB close to the joint surface is not advocated, as the expected risk for eventual joint arthroplasty remains low. Our study has several limitations. First, a control group without use of PMMA was not available. Ideally, we would have compared the results with the contralateral knees in the same patients or with curettage without use of PMMA. However, as radiographs were made for oncological follow-up, the contralateral knees were not depicted. Second, measurement of joint space narrowing would have been valuable for objective assessment of radiographic findings of osteoarthritis. The KL graded is determined on non-weight-bearing radiographs, as proposed in the original publication on this system [32] , and joint space narrowing could not be measured accurately.
In conclusion, the prevalence of osteoarthritis on the latest follow-up radiograph was increased after curettage and application of PMMA for GCTB around the knee. Large subchondral bone defects and close proximity to the joint surface increased the risk of osteoarthritis. The role of PMMA in osteoarthritis development remains unclear. Overall, functional outcomes and quality of life were unaltered for patients with radiographic findings of osteoarthritis. None of the patients required surgery for osteoarthritis at the time of intermediate follow-up, but the clinical relevance may increase over time as our study population was young and prolonged follow-up is advocated. Curettage and application of PMMA is a safe option for primary and recurrent GCTB, even with a large amount of subchondral bone involvement close to articular cartilage.
